Water Street Completes Dual Acquisitions to Continue Building Life Sciences Commercialisation Services Platform
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that it has completed two acquisitions to build a leading global life sciences’ commercialisation services platform. The health care firm has acquired Alliance Life Sciences (Alliance) and Health Strategies Group. Water Street will bring the two companies together with The Access Group, a business it acquired last year, under a global enterprise that will offer life sciences companies a suite of commercialisation services to support them with bringing new therapies to market, and gaining and sustaining market access and share.
“We are excited to be at the forefront of helping life sciences firms develop, manage and deliver new outcomes-based therapies that address specific patient populations and diseases,” said Jim Lang, an executive adviser with Water Street who will serve as executive chairman of the newly combined enterprise. “By bringing these two market-leading companies together with The Access Group, we are taking the next step toward building a global leader that will offer life sciences companies an integrated portfolio of solutions to help them bring the right therapies to the right patients at the right value.”
Alliance, founded in 2008, specialises in maximising revenue and optimising pricing for its customers. The firm offers a broad array of global pricing analytic tools and data, outsourced contract and revenue management services, including business process outsourcing, and digital marketing operational services.
Founded in 1992, Health Strategies Group is the leader in market access intelligence and customised research for pharmaceutical and biotech professionals. Its team of analysts dissects trends and identifies opportunities to help companies optimise their product access and distribution.
Emmanuel Doe, CEO, Alliance, stated: “Together with Health Strategies Group and The Access Group, we will offer our customers a deeper and more extensive portfolio of next-generation solutions that address the entire spectrum of their commercial needs. As one entity, we will have a greater impact on aligning outcomes among patients, caregivers, physicians and payers for pharmaceutical and medical device products.”
Alan Crowther, president of global markets, Alliance, added: “Our clients are working incredibly fast and hard to bring new and life-changing therapies to market. Building this new platform with Water Street enables us to combine our software development, data management and business process outsourcing capabilities with new services that will accelerate getting these therapies to the patients who need them.”
Water Street’s new global enterprise will work with life sciences companies to introduce new therapies and optimise existing therapies to targeted patient populations through the following suite of solutions:
- Strategic and Advisory Consulting Services
- Agency Implementation and Execution
- Research, Data and Analytics Products
- Turnkey Outsourced Operations
Alliance, Health Strategies Group and The Access Group will continue to operate under their current names and leadership teams. The executives of each company will report to the holding company’s board of directors spearheaded by Executive Chairman Jim Lang.
Financial details of the acquisitions are not being disclosed.
Alliance Life Sciences is a global innovator that delivers peace of mind and unlocks business value with unique solutions to complex commercial problems. With more than 15 years of dedicated life sciences experience, its worldwide team of experts provides insights and solves problems in contracting, pricing, reimbursement, and commercial operations. Alliance serves top pharmaceutical manufacturers, mid-market life sciences companies, and multiple medical device and diagnostic firms. For more information, visit www.alscg.com.
About Health Strategies Group
Health Strategies Group offers a dedicated team of research leaders committed to dissecting the trends, identifying customer needs, and pinpointing the barriers and opportunities for biopharma within the evolving health care environment. Recently, Health Strategies Group was ranked the No. 1 market research company that pharmaceutical and biotech executives would recommend for market access insights. For more information, visit healthstrategies.com.
About The Access Group
The Access Group—named a top 100 agency by MM&M five years in a row—offers a breadth of services to clients, from traditional “block-and-tackle” launch execution tactics to in-depth market assessments. The company is dedicated to complete product life cycle management—from prelaunch to loss of exclusivity—creating strategic brand solutions that drive demand across multiple stakeholder channels. The Access Group is committed to delivering strategic and tactical solutions that help companies overcome internal and external hurdles in the constantly evolving health care environment. For more information, visit http://theaccessgp.com.
About Water Street
Water Street is a strategic investor focused exclusively on health care. The firm has a strong record of building market-leading companies across key growth sectors in health care. It has worked with some of the world’s leading health care companies on its investments including Johnson & Johnson, Medtronic, Smith & Nephew and Walgreen Co. Water Street’s team is comprised of industry executives and investment professionals with decades of experience investing in and operating global health care businesses. The firm is headquartered in Chicago. For more information about Water Street, visit waterstreet.com.
+1 847 858 5230
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
First Westinghouse AP1000® Nuclear Plant Sanmen 1 Completes Initial Criticality21.6.2018 23:24 | Tiedote
Westinghouse Electric Company, China State Nuclear Power Technology Corporation (SNPTC) announced today that the world’s first AP1000 nuclear power plant located in Sanmen, Zhejiang Province, China has successfully completed initial criticality. “Today we completed the final major milestone before commercial operation for Westinghouse’s AP1000 nuclear power plant technology,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. “We are one step closer to delivering the world’s first AP1000 plant to our customer and the world – with our customers, we will provide our customers in China with safe, reliable and clean energy from Sanmen 1.” Following initial criticality will be connection to the electrical grid. Once plant operations begin at Sanmen 1, it will be the first AP1000 nuclear power plant in operation, offering innovative passive safety system technology, multiple layers of defense and advanced controls for unequaled reliability and safety. Commentin
Westinghouse Loads Fuel in Second AP1000® Nuclear Power Plant21.6.2018 23:07 | Tiedote
Westinghouse Electric Company and its customers, China State Nuclear Power Technology Corporation (SNPTC) and Shangdong Nuclear Power Company Limited (SDNPC) announced today that Haiyang Unit 1, the AP1000 nuclear power plant located in Haiyang, Shandong Province, China, has begun to load fuel. “This is a great day for Westinghouse, our China partners and the nuclear industry. Haiyang Unit 1 continues to demonstrate our ability to deliver safe, innovative solutions for power generation,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. He added, “Westinghouse will continue to deploy AP1000 technology throughout the world and demonstrate our technical leadership in the nuclear energy industry.” Fuel load at Haiyang Unit 1 commenced at 7:36 p.m. (GMT+8) today. Earlier this summer, in preparation for fuel load, Haiyang Unit 1 successfully completed the necessary testing and regulatory reviews conducted by China’s National Nuclear Safety Administration (NNS
Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 201821.6.2018 21:23 | Tiedote
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018. Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s Co-Founder and Chief Executive Officer said: “We are thrilled to bring this Phase 3 clinical trial to completion and we now expect to disclose top-line results by October of this year. Our PLEODRUG™ PXT3003 has already shown initial signals of efficacy in our Phase 2 trial in CMT1A. We are hopeful we can bring this much-needed therapy to patients suffering from this debilitating condition, as they currently have limited therapeutic options, mo
Philip Morris International Makes Call to Creative, Media and Communications Communities21.6.2018 21:13 | Tiedote
Philip Morris International Inc. (“PMI”) (NYSE: PM), today announced a bold call to action for the creative, media and communications communities to embrace its ongoing commitment to creating a smoke-free world. As part of this initiative, PMI will offer smoke-free alternatives wherever we can, including heated tobacco products and e-cigarettes, to current smokers in the industry who would otherwise continue to smoke. During a keynote at the PMI Science Lounge at The Cannes Festival of Creativity, SVP of Communications Marian Salzman said, “We are asking the creative community to join us in raising awareness of the potential of science, technology and innovation for those who smoke and the people around them.” The move is part of PMI’s vision to lead the charge towards greater innovation and technology in the tobacco industry, all of which is backed by science. Agencies interested in joining the movement can contact Marian Salzman at firstname.lastname@example.org. “People who smoke deserve in
IBC2018 Announces Cyber Security Forum to Help Media Tackle Cyber Threats21.6.2018 19:30 | Tiedote
IBC2018, the world’s most influential media, entertainment and technology show, today announces a Cyber Security Forum to expand its position as the preeminent cyber security destination for broadcasters and media. The event will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018, which last year attracted more than 57,000 attendees from 170 countries. The Cyber Security Forum is one-day, invitation-only event that will convene Chief Technology Officers, Chief Information Officers, Chief Information Security Officers and Chief Digital Officers within media and broadcasting for a conversation on the challenges and opportunities presented by cyber security for broadcasters. Attendees will discuss how to anticipate the next cyber threat, how to manage a breach and how to prepare for the future of cyber security. The Cyber Security Forum sits alongside the Telco & Media Innovation Forum and Leaders’ Forum as part of IBC’s Exec
Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe21.6.2018 19:23 | Tiedote
Mensia Technologies, french MedTech start up, leads the new booming category of Digital therapeutics with its revolutionary « at home « neurofeedback, to train the brain and cure neuropsy disorders without drugs. Co-founder INRIA-IT2, existing shareholders and now HARA, which are business angels experts in medical device category, joined this fund raise. BPI de Rennes is also part of this tour. Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in Rennes are computing real time signaling softwares. The neurofeedback technique is non invasive, at home and without drugs. MENSIA KOALA treats ADHD, Attention Deficit Disorders with or without Hyperactivity, children and adolescents. This unique medical device is a therapeutic video game on an interactive tablet connected to the brain activity. Children learn to control their attention by exercising 3 times a week during 4 months of treatment. Visual feedback given during the game, allows the children to learn, control and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme